Biogen Inc (BIIB)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Michel Vounatsos
Employees:
7,800
225 BINNEY STREET, CAMBRIDGE, MA 02142
7814642000

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 33.904 Billion Shares Outstanding146.893 Million Avg 30-day Volume 2.169 Million
P/E Ratio9.4434 Dividend Yield0.0 EPS2.22
Price to Revenue3.8675 Debt to Equity0.4464 EBITDA7.591 Billion
Price to Book Value4.1675 Operating Margin48.9821 Enterprise Value55.674 Billion
Current Ratio1.723 EPS Growth0.456 Quick Ratio1.307
1 Yr BETA 0.3713 52-week High/Low 468.55 / 217.1 Profit Margin40.9552
Operating Cash Flow Growth14.3979 Altman Z-Score4.7934 Free Cash Flow to Firm 6.542 Billion
View SEC Filings from BIIB instead.

View recent insider trading info

Funds Holding BIIB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BIIB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

711 total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KRAMER ROBIN CHIEF ACCOUNTING OFFICER

  • Officer
1,052 2021-12-08 5

IZZAR RACHID HEAD OF ALZHEIMER'S DISEASE

  • Officer
1,964 2021-12-02 2

MCDONNELL MICHAEL R EVP, CHIEF FINANCIAL OFFICER

  • Officer
19,515 2021-09-01 2

SHERWIN STEPHEN A

  • Director
17,103 2021-07-01 1

HAWKINS WILLIAM A

  • Director
2,820 2021-07-01 1

DORSA CAROLINE

  • Director
21,872 2021-07-01 1

PAPADOPOULOS STELIOS

  • Director
36,046 2021-07-01 1

JONES WILLIAM D /CA/

  • Director
775 2021-07-01 2

LEAMING NANCY

  • Director
13,763 2021-07-01 1

ROWINSKY ERIC K

  • Director
17,844 2021-07-01 1

DENNER ALEXANDER J

  • Director
656,729 2021-07-01 1

POSNER BRIAN S

  • Director
8,175 2021-07-01 2

MULLIGAN RICHARD

  • Director
13,729 2021-07-01 1

FREIRE MARIA C

  • Director
775 2021-07-01 2

MANTAS JESUS B

  • Director
3,718 2021-07-01 2

SANDROCK ALFRED HEAD OF RESEARCH & DEVELOPMENT

  • Officer
10,169 2021-06-07 4

GUINDO CHIRFI HEAD OF GLOB PROD STRAT & COM

  • Officer
2,919 2021-06-07 3

ALEXANDER SUSAN H EVP CHIEF LEGAL OFF & CORP SEC

  • Officer
10,870 2021-02-18 3

GREGORY GINGER EVP, HUMAN RESOURCES

  • Officer
10,150 2021-02-18 3

VOUNATSOS MICHEL CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
45,310 2021-02-18 3

GALDES ALPHONSE EVP PHARMACEUTICAL OPER & TECH

  • Officer
10,870 2021-02-18 3

PANGIA ROBERT W

  • Director
20,632 2020-12-31 0

CAPELLO JEFFREY D EVP & CHIEF FINANCIAL OFFICER

  • Officer
3,118 2020-02-12 0

KARP DANIEL EVP, CORPORATE DEVELOPMENT

  • Officer
930 2020-02-12 0

SCHENK LYNN

  • Director
12,132 2019-06-19 0

EHLERS MICHAEL D EVP, RESEARCH AND DEVELOPMENT

  • Officer
8,025 2019-06-01 0

MCKENZIE PAUL EVP PHARMACEUTICAL OPER & TECH

  • Officer
7,235 2019-03-01 0

COVINO GREGORY F VP, CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-03-01 0

KRESS JEAN-PAUL EVP PRES INT'L & GLOBAL HD GTO

  • Officer
0 2017-07-03 0

CLANCY PAUL J EXECUTIVE VP AND CFO

  • Officer
10,813 2017-04-25 0

DIPIETRO KENNETH EVP HUMAN RESOURCES

  • Officer
7,177 2017-02-28 0

KARABOUTIS ADRIANA EVP, TECH, BUS. SOL & CORP AFF

  • Officer
8,752 2017-02-28 0

SCANGOS GEORGE A CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
65,535 2016-07-21 0

KOPPEL ADAM EVP, STRATEGY AND BUS. DEV.

  • Officer
No longer subject to file 2016-06-06 0

ARTAVANIS-TSAKONAS SPYRIDON EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
3,150 2016-04-02 0

COX JOHN EVP PHARMACEUTICAL OPER & TECH

  • Officer
39,045 2016-04-01 0

HOLTZMAN STEVEN H EVP CORPORATE DEVELOPMENT

  • Officer
No longer subject to file 2016-02-23 0

WILLIAMS DOUGLAS E EVP RESEARCH & DEVELOPMENT

  • Officer
11,817 2015-06-19 0

KINGSLEY STUART A EVP, GLOBAL COMM. OPERATIONS

  • Officer
0 2015-02-23 0

YOUNG WILLIAM

  • Director
18,509 2014-01-08 0

PAWLICKI RAYMOND SVP, CHIEF INFORMATION OFFICER

  • Officer
8,710 2013-11-22 0

GAGNON ROBERT E. VICE PRESIDENT, FINANCE

  • Officer
3,999 2012-02-28 0

GRANATA FRANCESCO EVP GLOBAL COMMERCIAL OPERATIO

  • Officer
3,529 2012-02-01 0

SCHNEIER CRAIG ERIC EVP, HR, PUBLIC AFFAIRS & COMM

  • Officer
10,661 2011-03-01 0

MACLEAN MICHAEL F SVP, CHIEF ACCOUNTING OFFICER

  • Officer
10,681 2010-10-01 0

MULLEN JAMES C CEO & PRESIDENT

  • Officer
  • Director
No longer subject to file 2010-06-08 0

ROSS BRUCE

  • Director
No longer subject to file 2010-06-08 0

HAMM ROBERT A CHIEF OPERATING OFFICER

  • Officer
27,212 2010-04-23 0

LYTTON MICHAEL EVP CORPORATE & BUSINESS DEVEL

  • Officer
18,869 2010-03-02 0

PICKETT CECIL B PRESIDENT, R & D

  • Officer
  • Director
No longer subject to file 2009-10-02 0

DEKKERS MARIJN E

  • Director
6,595 2009-06-03 0

SHARP PHILIP A

  • Director
470,278 2009-06-03 0

HASLER HANS PETER CHIEF OPERATING OFFICER

  • Officer
53,261 2009-02-24 0

DUNN JOHN MICHAEL EVP, NEW VENTURES

  • Officer
No longer subject to file 2009-02-24 0

WIGGINS MARK C EVP CORP. AND BUS. DEV.

  • Officer
22,780 2008-09-26 0

HASNAIN FAHEEM EVP, ONCOLOGY/RHEUMATOLOGY SBU

  • Officer
25,454 2008-07-09 0

BEST LAWRENCE C

  • Director
5,600 2008-06-19 0

GLASSBERG ALAN

  • Director
5,600 2008-06-19 0

KELLER THOMAS F

  • Director
1,250 2007-10-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-10 16:10:20 -0500 2021-12-08 A 1,052 a 1,052 direct

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-07 16:09:08 -0500 2021-12-03 F 78 $223.92 d 1,132 direct -0.9756 0.4942 0.4942 6 -1.6871 5

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-07 16:09:08 -0500 2021-12-03 J 104 d 0 direct

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-07 16:09:08 -0500 2021-12-03 M 265 $223.92 a 1,210 direct -0.9756 0.4942 0.4942 6 -1.6871 5

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-07 16:09:08 -0500 2021-12-03 M 74 d 104 direct

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-07 16:09:08 -0500 2021-12-03 M 74 $223.92 a 945 direct -0.9756 0.4942 0.4942 6 -1.6871 5

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-07 16:09:08 -0500 2021-12-03 F 22 $223.92 d 1,110 direct -0.9756 0.4942 0.4942 6 -1.6871 5

KRAMER ROBIN - Officer CHIEF ACCOUNTING OFFICER

2021-12-07 16:09:08 -0500 2021-12-03 M 265 d 0 direct

IZZAR RACHID - Officer HEAD OF ALZHEIMER'S DISEASE

2021-12-06 16:14:53 -0500 2021-12-02 M 372 $228.52 a 1,271 direct 3.4784 1.7326 3.4784 2 0.0 1

IZZAR RACHID - Officer HEAD OF ALZHEIMER'S DISEASE

2021-12-06 16:14:53 -0500 2021-12-02 J 484 d 858 direct

IZZAR RACHID - Officer HEAD OF ALZHEIMER'S DISEASE

2021-12-06 16:14:53 -0500 2021-12-02 M 372 d 1,342 direct

IZZAR RACHID - Officer HEAD OF ALZHEIMER'S DISEASE

2021-12-06 16:14:53 -0500 2021-12-02 F 165 $228.52 d 1,106 direct 3.4784 1.7326 3.4784 2 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
BIOGEN INC BIIB 2022-01-19 22:15:03 UTC -0.2653 0.3353 3400000
BIOGEN INC BIIB 2022-01-19 21:45:03 UTC -0.2653 0.3353 3400000
BIOGEN INC BIIB 2022-01-19 21:15:04 UTC -0.2653 0.3353 3400000
BIOGEN INC BIIB 2022-01-19 20:45:03 UTC -0.2653 0.3353 3400000
BIOGEN INC BIIB 2022-01-19 20:15:03 UTC -0.2653 0.3353 3400000
BIOGEN INC BIIB 2022-01-19 19:45:03 UTC -0.2653 0.3353 3400000
BIOGEN INC BIIB 2022-01-19 19:15:03 UTC -0.2653 0.3353 3400000
BIOGEN INC BIIB 2022-01-19 18:45:03 UTC -0.2542 0.3242 3400000
BIOGEN INC BIIB 2022-01-19 18:15:03 UTC -0.2542 0.3242 3400000
BIOGEN INC BIIB 2022-01-19 17:45:03 UTC -0.2542 0.3242 3400000
BIOGEN INC BIIB 2022-01-19 17:15:04 UTC -0.2542 0.3242 3400000
BIOGEN INC BIIB 2022-01-19 16:45:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 16:15:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 15:45:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 15:15:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 14:45:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 14:15:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 13:45:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 13:15:03 UTC -0.2577 0.3277 3400000
BIOGEN INC BIIB 2022-01-19 12:45:03 UTC -0.2577 0.3277 3300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AGF Investments Trust- AGFIQ U.S. Market Neutral Momentum Fund BIIB -96.0 shares, $-23506.56 2020-12-31 N-PORT
Principal Funds, Inc- Global Multi-Strategy Fund BIIB 387.0 shares, $-131158.17 2021-08-31 N-PORT
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund BIIB -343.0 shares, $-97065.57 2021-09-30 N-PORT
VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND BIIB -391.0 shares, $-104271.88 2021-10-31 N-PORT
Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund BIIB -19.0 shares, $-5066.92 2021-10-31 N-PORT

Elevate your investments